VR Logo

Kymera Therapeutics Inc. (KYMR) download report


Healthcare | Biotechnology & Pharma Research

Kymera Therapeutics Inc. (KYMR) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

IPO Date: 21-Aug-2020

Co-Founder & Chairman: Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D.

Co-Founder, Pres, CEO & Director: Dr. Nello Mainolfi M.D., Ph.D.

Listing: NASDAQ: KYMR

Country: United States

Headquarters: Watertown, MA

Website: https://www.kymeratx.com

Key Facts

Market cap: $1,049.48 Mln

Revenue (TTM): $63.75 Mln

Earnings (TTM): $-123.83 Mln

Cash: $420.81 Mln

Total Debt: $17.47 Mln

Insider's Holding: 8.29%

Liquidity: Low

52 Week range: $13.15 - 69.12

Shares outstanding: 51,724,200

Stock Performance

Time Period Kymera Therapeutics (KYMR) S&P BSE Sensex S&P Small-Cap 600
YTD-66.77-9.18-18.78
1 month40.20-4.78-8.00
3 months-50.14-9.66-13.65
1 Year-56.490.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Kymera Therapeutics (KYMR) S&P Small-Cap 600 S&P BSE Sensex
20212.4025.2721.99